Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Abcellera Biologics Inc
ABCLCurrent price
2.42 USD
+0.05 USD (+2.11%)
Last closed
2.05 USD
Company
www.abcellera.com
ISIN
CA00288U1066
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
616 835 136 USD
Yield for 12 month
-38.11 %
1Y
3Y
5Y
10Y
15Y
ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. Address: 150 West 4th Ave, Vancouver, BC, Canada, V5Y 1G6
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
11.86 USDP/E ratio
–Dividend Yield
–Current Year
+28 833 000 USD
Last Year
+38 025 000 USD
Current Quarter
+5 050 000 USD
Last Quarter
+6 507 000 USD
Current Year
+28 833 000 USD
Last Year
+38 025 000 USD
Current Quarter
+5 050 000 USD
Last Quarter
-31 788 000 USD
Key Figures ABCL
1 year
3 years
5 years
10 years
EBITDA
-223 916 992 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-12.41 %
PEG Ratio
–
Return On Equity TTM
-14.75 %
Wall Street Target Price
11.86 USD
Revenue TTM
28 833 000 USD
Book Value
3.57 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-45.00 %
Dividend Yield
–
Gross Profit TTM
-138 426 000 USD
Earnings per share
-0.55 USD
Diluted Eps TTM
-0.55 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
45.90 %
Profit Margin
–
Dividend Analytics ABCL
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History ABCL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation ABCL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
27.47
Enterprise Value Revenue
2.89
Price Sales TTM
21.39
Enterprise Value EBITDA
5.30
Price Book MRQ
0.61
Financials ABCL
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ABCL
For 52 weeks
1.89 USD
4.34 USD
50 Day MA
2.64 USD
Shares Short Prior Month
22 787 356
200 Day MA
2.78 USD
Short Ratio
4.60
Shares Short
23 624 883
Short Percent
9.90 %
BeatStart